Gaucher disease is a rare, inherited metabolic disorder caused by the deficiency of the enzyme glucocerebrosidase. This in turn causes the accumulation of certain detrimental lipids in the body, especially the glycolipid glucocerebroside. The lipids are accumulated mainly within the macrophages, blood cells, spleen, liver, and bone marrow. Approximately 34 genetic mutations have been identified that leads to Gaucher disease, out of which there are four most prominent mutations that lead to more than half of the Gaucher disease globally. Some people may have no symptoms of this disease, while some experience severe complications. Some of the clinical manifestations of this disease are hepatosplenomegaly, anemia, thrombocytopenia, and skeletal abnormalities.

As per the Report, The Global Gaucher Disease market to grow at a CAGR of 7.60 percent over the period 2014-2019.

Covered in this Report
This report covers the present scenario and the growth prospects of the Global Gaucher Disease market for the period 2015-2019. To calculate the market size, the report considers revenue from the sales of various drugs used in the therapy of Gaucher disease, which includes:
• Enzyme replacement therapy
• Substrate reduction therapy

Based on the type of molecule used for the treatment of Gaucher disease, the market is categorized into two segments:
• Biologics
• Small Molecules

Based on the route of administration adopted for the treatment of Gaucher disease, the market is categorized into two segments:
• Oral
• Parenteral

Based on the dosage forms of the drugs used to treat the disease, the Global Gaucher Disease market is categorized into two segments:
• Solid
• Liquid

Global Gaucher Disease Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Gaucher Disease market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions
• Americas
• APAC
• EMEA

Key Vendors
• Actelion Pharmaceuticals
• Genzyme
• Pfizer
• Shire

Other Prominent Vendors
• Amicus Therapeutics
• Belrose Pharma
• Bionaturis
• Biosidus
• ISU Abxis
• JCR Pharmaceuticals
• LIXTE Biotechnology

Market Driver
• Special Provisions for Orphan Drugs
• For a full, detailed list, view our report

Market Challenge
• Limited Patient Population
• For a full, detailed list, view our report

Market Trend
• Regulatory Assistance in Emerging Nations
• For a full, detailed list, view our report

Key Questions Answered in this Report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

Table of Contents
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
04. Market Research Methodology
05. Introduction
06. Disease Overview
07. Pipeline Analysis
08. Market Landscape
09. Market Segmentation by Type of Therapy
10 Market Segmentation by Type of Molecule